An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder

Annals of General Psychiatry
Anish Shah, Joanne Northcutt

Abstract

Despite the current treatments available for panic disorder (PD), as many as one-third of patients have persistent and treatment-resistant panic attacks. Vortioxetine is an approved medicine for major depressive disorder and has been shown to have anxiolytic properties. The purpose of this study was to evaluate its efficacy and safety in an adult population with a diagnosis of PD. The study design was open label with flexible dose strategies (5, 10, or 20 mg) with a treatment period of 10 weeks. 27 male and female subjects aged between 18 and 60 years, who met DSM-IV criteria for PD with or without agoraphobia, or who had a Panic Disorder Severity Scale (PDSS) score > 8 at baseline were enrolled. Statistical significance was established by the Student's T test. A statistically significant decrease in the occurrence of panic attacks was measured with the PDSS with vortioxetine. In addition, a moderate improvement in the quality of life and no significant side effects were observed using the Quality-of-Life Scale and Monitoring of Side Effects Scale, respectively. These results provide some support for the use of vortioxetine in the management of panic disorder.Trial registration ClinicalTrials.gov ID#: NCT02395510. Registered Ma...Continue Reading

References

Nov 14, 1997·The American Journal of Psychiatry·M K ShearL A Papp
Oct 10, 2001·Journal of Psychiatric Research·M K ShearT Wang
Apr 5, 2005·The International Journal of Neuropsychopharmacology·Abraham BakkerDan J Stein
Apr 6, 2006·Archives of General Psychiatry·Ronald C KesslerEllen E Walters
Apr 22, 2006·BMJ : British Medical Journal·C Barr Taylor
Sep 19, 2006·Lancet·Peter P Roy-ByrneMurray B Stein
Feb 6, 2007·CNS Spectrums·Kelly PosnerMadelyn Gould
Feb 1, 2007·Neuropsychiatric Disease and Treatment·Martin A Katzman, Leslie Jacobs
Oct 10, 2009·The Journal of Clinical Psychiatry·Naomi M SimonMark H Pollack
Nov 18, 2011·Neuropsychiatric Disease and Treatment·Giampaolo PernaDaniela Caldirola
Feb 14, 2012·Assessment·Meghan E KeoughNaomi M Simon
Aug 18, 2012·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Leszek BidzanDavid V Sheehan
Sep 26, 2013·Psychotherapy and Psychosomatics·Emanuela OffidaniGiovanni Andrea Fava
Feb 27, 2014·Neuropsychiatric Disease and Treatment·Cornelius L Katona, Cara P Katona
Oct 8, 2014·International Journal of Psychiatry in Clinical Practice·Giulia CamuriA Carlo Altamura
Feb 18, 2015·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Atul R MahableshwarkarRichard S E Keefe
May 2, 2015·International Clinical Psychopharmacology·Borwin BandelowDirk Wedekind
Dec 5, 2015·Expert Opinion on Pharmacotherapy·Rafael C FreireAntonio E Nardi
Dec 19, 2015·Expert Opinion on Pharmacotherapy·K Ryan Connolly, Michael E Thase
Feb 3, 2016·Current Psychiatry Reports·Giampaolo PernaDaniela Caldirola
Apr 7, 2016·Expert Review of Neurotherapeutics·Laura OrsoliniDomenico De Berardis

❮ Previous
Next ❯

Citations

Jan 31, 2019·Psychiatry Investigation·Morena M ZuglianiRafael C Freire
Aug 31, 2019·Pharmacology & Therapeutics·Simone B Sartori, Nicolas Singewald
Jan 12, 2021·Frontiers in Psychiatry·Amir GarakaniDan V Iosifescu
Feb 16, 2021·Journal of Clinical Psychopharmacology·Boadie W DunlopPhilip D Harvey
Apr 24, 2021·Journal of Experimental Pharmacology·Daniela CaldirolaGiampaolo Perna
Jun 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Nazlı Turan YücelÖzgür Devrim Can

❮ Previous
Next ❯

Software Mentioned

R
TREND
R foundation for

Related Concepts

Related Feeds

Anxiety Disorders

Discover the latest research on anxiety disorders including agoraphobia, panic disorder, obsessive-compulsive disorder, and post-traumatic stress disorder here.